Rapid Neurologic Deterioration in a Healthy Child at 4000 Meters: A Case Report and Literature Review of High Altitude Cerebral Edema in Children.

Wilderness Environ MedFeb 10, 2026 (epub)

Oliver von Olnhausen, Henrik Hedelin, Olivia Kiwanuka

✦ AI-curated · Sources linked

Case in brief

A previously healthy 10-year-old boy developed headache, nausea, impaired consciousness, and ataxia at 4000 m on Mount Kilimanjaro. The presentation was consistent with high-altitude cerebral edema (HACE), and he required assisted evacuation. After an immediate descent of 2295 m, he recovered completely within 24 hours and had no long-term sequelae.

What made this case unusual

The report highlights the limited published experience with pediatric HACE: the authors’ review found only one prior case series, involving two patients aged 12 and 16 years. Recognition and management in field conditions without medical support were central challenges.

Diagnostic / clinical pearl

In a child at altitude, headache, nausea, altered consciousness, and ataxia should prompt consideration of HACE; early recognition and descent are central to management.

Why it matters

Pediatric HACE guidance on descent, supplemental oxygen, and dexamethasone is extrapolated from adult data, underscoring the limited evidence base for children.

Source

Published in Wilderness Environ Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.